Continuous administration of recombinant human endostatin (Endostar): A pre-clinical safety study

Experimental and Therapeutic Medicine

Volumn 3, Issue 6, 2012, Pages 1018-1022

  Huang, Ruofan ^a,b   Zhan, Qiong ^a,b   Zhou, Xinli ^a,b   Chu, Zhaohui ^a,b   Jiang, Jingwei ^a,b   Liang, Xiaohua ^a,b  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Endostatin; Microvessel count; Safety; Vascular endothelial cells

Indexed keywords

RECOMBINANT ENDOSTATIN; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL COUNT; CONTINUOUS INFUSION; CONTROLLED STUDY; DENSITY; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG SCREENING; ENDOTHELIUM CELL; FEMALE; HEART MUSCLE INJURY; KIDNEY INJURY; LUNG INJURY; MICROVASCULATURE; MOUSE; NONHUMAN; OSMOTIC PUMP; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

EID: 84859463819     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.534     Document Type: Article

References (13)

1. Jiang LP, Zou C, Yuan X, Luo W, Wen Y and Chen Y: N-terminal modification increases the stability of the recombinant human endostatin in vitro. Biotechnol Appl Biochem 54: 113-120, 2009.
2. Han B, Xiu Q, Wang H, Shen J, Gu A and Luo Y: A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer. J Thorac Oncol 6: 1104-1109, 2011.
3. Paborsky LR, Dunn KE, Gibbs CS and Dougherty JP: A nickel chelate microtiter plate assay for six histidine-containing proteins. Anal Biochem 234: 60-65, 1996.
4. Weidner N, Carroll PR, Flax J, Blumenfeld W and Folkman J: Tumor angiogenesis correlation with metastasis in invasive prostate carcinoma. Am J Pathol 143: 401-409, 1993.
5. Shaked Y, Henke E, Roodhart JM, et al: Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14: 263-273, 2008.
6. Celik I, Surucu O, Dietz C, et al: Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res65: 11044-11050, 2005.
7. Despoix N, Walzer T, Jouve N, et al: Mouse CD146/MCAM is a marker of natural killer cell maturation. Eur J Immunol 38: 2855-2864, 2008.
8. Dallas NA, Samuel S, Xia L, et al: Endoglin (CD105): A marker of tumor vasculature and potential target for therapy. Clin Cancer Res14: 1931, 2008.
9. Khan SS, Solomon MA and McCoy JP Jr: Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry. Cytometry B Clin Cytom 64: 1-8, 2005.
10. Abdelmoneim SS, Talwalkar J, Sethi S, Kamath P, et al: A prospective pilot study of circulating endothelial cells as a potential new biomarker in portal hypertension. Liver Int 30: 191-197, 2010.
11. Goon PK, Boos CJ and Lip GY: Circulating endothelial cells: markers of vascular dysfunction. Clin Lab 51: 531-538, 2005.
12. Dome B, Timar J, Ladanyi A, Paku S, Renyi-Vamos F, Klepetko W, etal: Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: from biology to therapy. Crit Rev Oncol Hematol 69: 108-124, 2009.
13. Erdbruegger U, Haubitz M and Woywodt A: Circulating endothelial cells: A novel marker of endothelial damage. Clin Chim Acta 373: 17-26, 2006.